[go: up one dir, main page]

MX2018005305A - Nuevos antiestrogenos heterociclicos. - Google Patents

Nuevos antiestrogenos heterociclicos.

Info

Publication number
MX2018005305A
MX2018005305A MX2018005305A MX2018005305A MX2018005305A MX 2018005305 A MX2018005305 A MX 2018005305A MX 2018005305 A MX2018005305 A MX 2018005305A MX 2018005305 A MX2018005305 A MX 2018005305A MX 2018005305 A MX2018005305 A MX 2018005305A
Authority
MX
Mexico
Prior art keywords
antiestrogens
heterociclic
new
new heterociclic
antagonists
Prior art date
Application number
MX2018005305A
Other languages
English (en)
Other versions
MX385940B (es
Inventor
Dilipbhai Aradhye Jayraj
Mohanbhai Panchal Bhavesh
Kumar Pal Ranjan
Nitinkumar Desai Japan
Pankajbhai Pathak Sandeep
Rao Chitturi Trinadha
Pravinbhai Sedani Amit
Dhanjibhai Prajapati Kaushikkumar
Pinakin Rana Dijixa
Ghosh Indraneel
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MX2018005305A publication Critical patent/MX2018005305A/es
Publication of MX385940B publication Critical patent/MX385940B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invención proporciona nuevos compuestos heterocíclicos como agentes anticancerígenos, especialmente como antagonistas o degradantes 5 del receptor de estrógeno (ER), así como el proceso para su preparación.
MX2018005305A 2015-10-27 2016-10-26 Nuevos antiestrógenos heterocíclicos. MX385940B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4058MU2015 2015-10-27
PCT/IN2016/050364 WO2017072792A1 (en) 2015-10-27 2016-10-26 Novel heterocyclic antiestrogens

Publications (2)

Publication Number Publication Date
MX2018005305A true MX2018005305A (es) 2019-04-29
MX385940B MX385940B (es) 2025-03-18

Family

ID=58629986

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005305A MX385940B (es) 2015-10-27 2016-10-26 Nuevos antiestrógenos heterocíclicos.

Country Status (28)

Country Link
US (2) US10865199B2 (es)
EP (2) EP4043438A1 (es)
JP (2) JP6855475B2 (es)
KR (1) KR20180088375A (es)
CN (1) CN108699021B (es)
AU (1) AU2016347679B2 (es)
BR (1) BR112018008375B1 (es)
CA (1) CA3001958A1 (es)
CY (1) CY1125153T1 (es)
DK (1) DK3368519T3 (es)
EA (1) EA034131B1 (es)
ES (1) ES2916223T3 (es)
HR (1) HRP20220640T1 (es)
HU (1) HUE059386T2 (es)
IL (2) IL283559B (es)
LT (1) LT3368519T (es)
MX (1) MX385940B (es)
PH (1) PH12018500829A1 (es)
PL (1) PL3368519T3 (es)
PT (1) PT3368519T (es)
RS (1) RS63217B1 (es)
SA (1) SA518391423B1 (es)
SG (2) SG10201913001SA (es)
SI (1) SI3368519T1 (es)
SM (1) SMT202200213T1 (es)
UA (1) UA122348C2 (es)
WO (1) WO2017072792A1 (es)
ZA (1) ZA201802615B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913001SA (en) * 2015-10-27 2020-03-30 Sun Pharma Advanced Res Co Ltd Novel heterocyclic antiestrogens
LT3386500T (lt) 2015-12-09 2022-12-27 The Board Of Trustees Of The University Of Illinois Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
CA3048057A1 (en) 2017-01-06 2018-07-12 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
WO2018148576A1 (en) 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
KR20220046586A (ko) 2019-07-22 2022-04-14 썬 파마 어드밴스트 리서치 컴패니 리미티드 선택적 에스트로겐 수용체 분해제

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
DE69023906T2 (de) 1990-08-09 1996-04-11 Council Scient Ind Res Benzopyrane und Verfahren zu deren Herstellung.
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
WO1999002512A1 (en) 1997-07-09 1999-01-21 Novo Nordisk A/S Dl-2,3-diaryl-2h-1-benzopyrans
DE10013782A1 (de) * 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
WO2004091488A2 (en) * 2003-04-14 2004-10-28 Merck & Co., Inc. Estrogen receptor modulators
EP1846397A1 (en) * 2005-01-21 2007-10-24 Janssen Pharmaceutica N.V. Novel heterocyclic benzoy[c]chromene derivatives useful as modulators of the estrogen receptors
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
EP2580210B1 (en) 2010-06-10 2017-03-01 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
AP2014007657A0 (en) 2011-12-16 2014-05-31 Olema Pharmaceuticals Inc Novel benzopyran compounds, compositions and uses thereof
WO2014205138A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
KR20160021281A (ko) 2013-06-19 2016-02-24 세라곤 파마슈티컬스, 인크. 아제티딘 에스트로겐 수용체 조절제 및 이의 용도
WO2016097073A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
JP6768711B2 (ja) 2015-05-26 2020-10-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 複素環式エストロゲン受容体モジュレーター及びその使用
SG10201913001SA (en) * 2015-10-27 2020-03-30 Sun Pharma Advanced Res Co Ltd Novel heterocyclic antiestrogens

Also Published As

Publication number Publication date
EA034131B1 (ru) 2020-01-09
DK3368519T3 (da) 2022-05-23
JP6855475B2 (ja) 2021-04-07
SA518391423B1 (ar) 2021-03-31
SG10201913001SA (en) 2020-03-30
SMT202200213T1 (it) 2022-07-21
JP2018536647A (ja) 2018-12-13
EP3368519A4 (en) 2019-04-10
WO2017072792A1 (en) 2017-05-04
EA201890981A1 (ru) 2018-09-28
EP4043438A1 (en) 2022-08-17
JP2021098749A (ja) 2021-07-01
JP7052111B2 (ja) 2022-04-11
BR112018008375B1 (pt) 2023-12-12
LT3368519T (lt) 2022-06-10
RS63217B1 (sr) 2022-06-30
EP3368519A1 (en) 2018-09-05
IL283559A (en) 2021-07-29
CN108699021B (zh) 2022-10-04
US11465990B2 (en) 2022-10-11
HRP20220640T1 (hr) 2022-07-08
PT3368519T (pt) 2022-05-25
ZA201802615B (en) 2022-10-26
CY1125153T1 (el) 2024-12-13
CN108699021A (zh) 2018-10-23
PH12018500829A1 (en) 2018-10-15
EP3368519B1 (en) 2022-04-06
ES2916223T3 (es) 2022-06-29
IL258949B (en) 2021-06-30
SI3368519T1 (sl) 2022-07-29
IL258949A (en) 2018-06-28
IL283559B (en) 2022-07-01
AU2016347679B2 (en) 2020-06-25
HUE059386T2 (hu) 2022-11-28
US10865199B2 (en) 2020-12-15
AU2016347679A1 (en) 2018-05-10
US20210053947A1 (en) 2021-02-25
BR112018008375A2 (pt) 2018-10-23
SG11201803119XA (en) 2018-05-30
MX385940B (es) 2025-03-18
PL3368519T3 (pl) 2022-06-06
UA122348C2 (uk) 2020-10-26
US20180354936A1 (en) 2018-12-13
CA3001958A1 (en) 2017-05-04
KR20180088375A (ko) 2018-08-03

Similar Documents

Publication Publication Date Title
NI201800075A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos.
CL2015003491A1 (es) Compuestos químicos.
MX378998B (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
DK3464249T3 (da) Substituerede carbonnukleosidderivater, der er anvendelige som anticancermidler
CR20180563A (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que lo contienen
CL2017001181A1 (es) Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4(sstr4)
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CY1125153T1 (el) Νεα ετεροκυκλικα αντiοιστρογονα
MX2017014375A (es) Moduladores del ccr2.
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
CO2017005959A2 (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CO2017000065A2 (es) Indoles funcionalizados y sustituidos como agentes anti-cáncer
MX2016014555A (es) Composiciones novedosas, usos y metodos para hacerlas.
CL2016002084A1 (es) Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina.
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
CL2018001085A1 (es) Derivados de indolin-2-ona
DOP2016000211A (es) Pirazinas moduladoras de gpr6
CL2016002515A1 (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1.
CL2016002064A1 (es) Derivados de etinilo.
CL2017002163A1 (es) Derivado de imidazopirimidina e imidazotriazina, y composición farmacéutica que lo comprende.
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
MX391764B (es) Procedimiento para la preparación de clorhidrato de piperidina-4-carbotioamida.
IN2014MU00001A (es)